Powder: -20°C for 3 years | In solvent: -80°C for 1 year
T56-LIMKi (T5601640) 是一种选择性LIMK2抑制剂,抑制Panc-1细胞生长的IC50值为35.2 μM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 233 | 现货 | ||
2 mg | ¥ 329 | 现货 | ||
5 mg | ¥ 538 | 现货 | ||
10 mg | ¥ 863 | 现货 | ||
25 mg | ¥ 1,730 | 现货 | ||
50 mg | ¥ 2,770 | 现货 | ||
100 mg | ¥ 4,260 | 现货 | ||
500 mg | ¥ 8,970 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 593 | 现货 |
产品描述 | T56-LIMKi (T5601640) is a selective inhibitor of LIMK2. |
靶点活性 | LIMK2:35.2 μM. |
体外活性 | T56-LIMKi efficiently inhibits the growth of ST88-14, U87, Panc-1 cells, A549 lung cancer cells with IC50 values of 18.3, 7.4, 35.2 and 90 μM, respectively. T56-LIMKi decreases phosphorylated cofilin (p-cofilin) levels and accordingly inhibits the growth of several cancerous cell lines, including those of pancreatic cancer, glioma and schwannoma[1]. It blocks the phosphorylation of cofilin which leads to actin severance and inhibition of tumor cell migration, tumor cell growth, and anchorage-independent colony formation in soft agar. T56-LIMKi (10-50 μM) reduces p-cofilin in a dose-dependent manner in NF1−/−MEFs with an IC50 of 30 μM. Notably, the inhibitor does not affect the amounts of total cofil. 50 μM T56-LIMKi causes a statistically significant reduction in the number of cells exhibiting stress fibers[2]. |
体内活性 | T56-LIMKi can induce inhibition of cofilin phosphorylation and Panc-1 tumor shrinkage in vivo. Mice treated with T56-LIMKi (60 mg/kg) display a significant decrease in tumor volume than controls[1]. |
细胞实验 | T56-LIMKi can induce inhibition of cofilin phosphorylation and Panc-1 tumor shrinkage in vivo. Mice treated with T56-LIMKi (60 mg/kg) shows a significant decrease in tumor volume compared to control[1]. |
别名 | T5601640 |
分子量 | 389.33 |
分子式 | C19H14F3N3O3 |
CAS No. | 924473-59-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (128.43 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.5685 mL | 12.8426 mL | 25.6852 mL | 64.2129 mL |
5 mM | 0.5137 mL | 2.5685 mL | 5.137 mL | 12.8426 mL | |
10 mM | 0.2569 mL | 1.2843 mL | 2.5685 mL | 6.4213 mL | |
20 mM | 0.1284 mL | 0.6421 mL | 1.2843 mL | 3.2106 mL | |
50 mM | 0.0514 mL | 0.2569 mL | 0.5137 mL | 1.2843 mL | |
100 mM | 0.0257 mL | 0.1284 mL | 0.2569 mL | 0.6421 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
T56-LIMKi 924473-59-6 Cell Cycle/Checkpoint LIM Kinase T-56-LIMKi T56LIMKi inhibit LIM Kinase (LIMK) T5601640 LIMKs Inhibitor T-5601640 T 5601640 T56 LIMKi inhibitor